European regulators recommended Vynfinit's approval for ovarian cancer and a mid-stage lung cancer study was successful.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Bloomberg's Drew Armstrong and ISI Group's Mark Schoenebaum discuss Gilead, Sovaldi and the controversy of Medicaid reimbursement.
Cologuard was able to detect more cancer and pre-cancerous lesions than a comparator test but also caused more false positives.
When your job is helping MannKind sell stock, it's not hard to be a bull.
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.
The SEC investigation into Galena began in February, following an exclusive story by TheStreet.
The company intends to seek accelerated approval in the U.S. for OCA, based on the positive results from the phase III study in PBC patients.
Intercept discloses cardiovascular events reported in a study of the company's fatty liver disease drug.
Gilead has transformed itself with tremendous success twice already and is now working on plan number three.